The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
December 6th 2023
A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.
Lower Sleep Efficiency Linked to Higher HbA1c in Adolescents with Type 1 Diabetes
December 2nd 2023The study did not find an association between glycemic parameters and flow-mediated dilation, but they did find associations between lower sleep efficiency with poorer glycemic control, insulin resistance, estimated glucose disposal rate, and HbA1C.
FIDELITY Analysis Details Benefits of Early Albuminuria Reduction in CKD
November 2nd 2023Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.
Endocrine Case Report: Confusion and Shaking
October 28th 2023This endocrine case report from Brady Pregerson, MD features a 32-year-old female with a history of polycystic ovary syndrome and diabetes who presents to the emergency department for sudden trouble swallowing, confusion, and shakiness. Can you determine the correct diagnosis?
PROTECT: Teplizumab Preserves Beta-Cell Function in Newly Diagnosed Type 1 Diabetes
October 18th 2023In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.
Racial Disparities in Diabetes Management Go Beyond Insurance Status, Study Finds
October 17th 2023Despite access to care and health insurance, Hispanic and non-Hispanic Black individuals with diabetes experience poorer glycemic control compared to non-Hispanic White counterparts, revealing persistent racial disparities in healthcare.
Novo Nordisk Halts Semaglutide Kidney Outcomes Trial for Early Efficacy
October 11th 2023On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.